Business
Valeo Pharma Reports its First Quarter 2021 Results and Highlights
Valeo Pharma Reports its First Quarter 2021 Results and Highlights.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Reports its First Quarter 2021 Results and Highlights\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Reports its First Quarter 2021 Results and Highlights\nCanada NewsWire\nMONTREAL, March 31, 2021\n\n\n\nValeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies Q1-21 net revenues of $1.9 million, up 11 % vs Q1-20Frederic Fasano appointed as President and Chief Operating OfficerRedesca® and Redesca HP® receive Health Canada approval, launching in Q3 Hesperco™ capsules at the core of a Montreal Heart Institute's COVID-19 study MONTREAL, March 31, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021.\n\n \n \n \n \n \n \n\n \n\"Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually1  and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.\", said Steve Saviuk, Valeo's CEO. \"With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology's ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo's history\".\nCommenting on the first quarter 2021 results, Luc Mainville, Senior Vice-President and Chief Financial Officer said, \"Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter r...